Abstract
Data on 16 potential risk factors for myelosuppression were assessed in 134 patients who received either vindesine and cisplatin (VP) or mitomycin C, vindesine and cisplatin (MVP) for inoperable stage III or IV non‐small cell lung cancer in a randomized trial. Determinant factors for myelosuppression were evaluated by using univariate analysis and the logistic regression model. Recursive partitioning and amalgamation (RPA) was also used to define patient subgroups frequently suffering from severe bone marrow toxicity. Overall, 33 (25%) of 134 patients experienced at least one episode of grade 4 leukopenia. In univariate analysis, age, body surface area, serum creatinine, and pretreatment hemoglobin concentration were associated with severe leukopenia. A multivariate analysis using the logistic regression method showed that only raised creatinine level was an independent predictor for grade 4 leukopenia (P=0.049). The RPA model generated three distinct subgroups based on age, body surface area and regimen. The three subgroups were distinguished by the frequency of severe (grade 4) leukopenia (50%, 25%, and 2.4%, respectively) (P<0.001). Grade 4 leukopenia occurred more frequently in patients in class 3 (age ≥65 years and treatment with MVP). The RPA model was useful in identifying the risk factors for myelosuppression induced by cisplatin‐based chemotherapy, and in defining patient subgroups with elevated risk of toxicity.
Keywords: Cisplatin‐based chemotherapy, Non‐small cell lung cancer, Bone marrow suppression, Elderly patient, Recursive partitioning and amalgamation
Full Text
The Full Text of this article is available as a PDF (388.6 KB).
REFERENCE
- 1.Gralla , R. J. , Casper , E. S. , Kelsen , D. P. , Braun , D. W. , Dukeman , M. E. , Martini , N. , Young , C. W. and Golbey , R. B.Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules . Ann. Intern. Med ., 95 , 414 – 420 ( 1981. ). [DOI] [PubMed] [Google Scholar]
- 2.Kawahara , M. , Furuse , K. , Kodama , N. , Yamamoto , M. , Kubota , K. , Takada , M. , Negoro , S. , Kusunoki , Y. , Matsui , K. , Takifuji , N. and Fukuoka , M.A randomized study of cisplatin versus cisplatin plus vindesine for non‐small cell lung cancer . Cancer , 68 , 714 – 719 ( 1991. ). [DOI] [PubMed] [Google Scholar]
- 3.Fukuoka , M. , Negoro , S. , Masuda , N. , Kusunoki , Y. , Matsui , K. , Ryu , S. , Takifuji , N. , Kudoh , S. and Takada , M.Mitomycin C, vindesine, and cisplatin in advanced non‐small‐cell lung cancer . Am. J. Clin. Oncol ., 15 , 18 – 22 ( 1992. ). [DOI] [PubMed] [Google Scholar]
- 4.Burkes , R. L. , Ginsberg , R. J. , Shepherd , F. A. , Blackstein , M. E. , Goldberg , M. E. , Waters , P. F. , Patterson , G. A. , Todd , T. , Pearson , F. G. , Cooper , J. D.Jones , D. and Lockwood , G.Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non‐small cell lung cancer; results of the Toronto phase II trial . J. Clin. Oncol ., 10 , 580 – 586 ( 1992. ). [DOI] [PubMed] [Google Scholar]
- 5.Kris , R. J. , Gralla , R. J. and Wertheim , M. S.Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non‐small cell lung cancer . Cancer Treat. Rep ., 70 , 1091 – 1096 ( 1986. ). [PubMed] [Google Scholar]
- 6.Holmes , E. C. and Ruckdeschel , J. C.Preoperative chemotherapy for locally advanced non‐small cell lung cancer . Semin. Oncol ., 21 , 97 – 100 ( 1994. ). [PubMed] [Google Scholar]
- 7.Zagonel , V. , Tirelli , U. , Serraino , D. , Lo Re , G. , Merola , M. C. , Mascarin , M. , Trobo , G. M. , Carbone , A. and Monfardini , S.The aged patient with lung cancer . Drug Aging , 4 , 34 – 46 ( 1994. ). [DOI] [PubMed] [Google Scholar]
- 8.Balducci , L. , Parker , M. , Sexton , W. and Tantranond , P.Pharmacology of antineoplastic agents in the elderly patient . Semin. Oncol ., 16 , 76 – 84 ( 1989. ). [PubMed] [Google Scholar]
- 9.Fukuoka , M. , Masuda , N. , Furuse , K. , Negoro , S. , Takada , M. , Matsui , K. , Takifuji , N. , Kudoh , S. , Kawahara , M. , Ogawara , M. , Kodama , N. , Kubota , K. , Yamamoto , M. and Kusunoki , Y.A randomized trial in inoperable non‐small‐cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin . J. Clin. Oncol ., 9 , 606 – 613 ( 1991. ). [DOI] [PubMed] [Google Scholar]
- 10.World Health Organization. “ WHO Handbook for Reporting Results of Cancer Treatment ,” WHO Offset Publication No. 48 . World Health Organization ( 1979. ), World Health Organization; , Geneva , Switzerland . [Google Scholar]
- 11.Cox , D. R.Regression model and life tables . J. R. Stat. Soc ., 34 , 187 – 220 ( 1972. ). [Google Scholar]
- 12.Ciampi , A. , Chang , C.‐H. , Hogg , S. and McKinney , S.Recursive partition; a versatile method for exploratory data analysis in biostatics . In “Biostatistics ,” ed. MacNeill I. B. and Umphery G. J. , pp. 23 – 50 ( 1987. ). D. Reidel Publishing Company; , Dordrecht . [Google Scholar]
- 13.Dennis , V. W.Investigations of renal function . In “Cecil Textbook of Medicine ,” ed. Wyngaarden J. B. and Smith L. H., Jr. , pp. 520 – 528 ( 1988. ). W.B. Saunders Company; , Philadelphia . [Google Scholar]
- 14.Solomon , D. , Brown , A. S. , Brummel‐Smith , K. , Burgess , L. , D'Agostino , R. B. , Goldschmidt , J. W. , Halter , J. B. , Hazzard , W. R. , Jahnigen , D. W. , Phelps , C. , Raskind , M. , Schrier , R. W. , Sox , Jr. , H. C. , Williams , S. V. and Wykle , M.National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision‐making . J. Am. Geriatr. Soc ., 36 , 342 – 347 ( 1988. ). 3280648 [Google Scholar]
- 15.Chatta , G. S. , Price , T. H. , Stratton , J. R. and Dale , D. C.Aging and marrow neutrophil reserves . J. Am. Geriatr. Soc ., 42 , 77 – 81 ( 1994. ). [DOI] [PubMed] [Google Scholar]
- 16.Hoagland , H.Hematologic complications of cancer chemotherapy . Semin. Oncol ., 9 , 95 – 102 ( 1982. ). [PubMed] [Google Scholar]
- 17.Ettinger , D.Metastatic non‐small cell lung cancer . Lung Cancer , 9 ( Suppl. ), S69 – S79 ( 1993. ). [Google Scholar]
- 18.Miller , A. , Herndon , II J. , Hollis , D. , Ellerton , J. , Langleben , A. , Richards , IIF. and Green , M.Schedule dependency of 21‐day oral versus 3‐day intravenous etoposide in combination with intravenous cisplatin in extensive‐stage small‐cell lung cancer: a randomized phase III study of the cancer and leukemia Group B . J. Clin. Oncol ., 13 , 1871 – 1879 ( 1995. ). [DOI] [PubMed] [Google Scholar]
- 19.The American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony‐stimulating factors: evidence‐based, clinical practice guidelines . J. Clin. Oncol ., 12 , 2471 – 2508 ( 1994. ). [DOI] [PubMed] [Google Scholar]